Impact of PSMA PET on Radiation Oncology Planning.

Radiation therapy (RT) plays a critical role in managing prostate cancer (PCa) in various stages, from localized disease to metastatic settings. Recent advancements in molecular imaging using prostate-specific membrane antigen positron emission tomography (PSMA-PET) have revolutionized PCa diagnosis, significantly enhancing local, lymph node and distant stagingto conventional imaging methods. This narrative review explores the impact of PSMA-PET on RT planning, highlighting its diagnostic performance and implications for RT treatment management. PSMA-PET has shown superior sensitivity in detecting metastatic lesions and intraprostatic tumor volumes, leading to more accurate disease staging and treatment planning. The HypoFocal trials investigate the safety and efficacy of implementing PSMA-PET into definitive RT regimens. Additionalongoing clinical trials are investigating the potential of PSMA-PET-based RT recurrent and oligometastatic PCa. Despite these advancements, further research is necessary to optimize patient selection and define the best management strategies for PSMA-PET-guided RT.